References:

1. Chowdary, K.P.R. and Madhavi, B.L.R, **Indian Drugs**, 42(9), 2005, 557.
2. K.H.Fromming and J.Szejtli, **Cyclodextrins in Pharmacy**, Kluwer Academic Publications, Dordrecghi, p.20 (1994).
3. D.Duchene and D.Woussidjewe, in ed.: S.Dumitriu, **Polysaccharides in Medical Applications.** Marcel Dekker, New York, p. 575 (1996).
4. D.O. Thompson, **Crit. Rev.Ther. Drug Carrier Syst. 14**, 1 (1997).
5. A.R.Hedges, **Chem. Rev.,98**, 2035 (1998).
6. Martin A, Bustamante, P. and chun, A.H.C., Eds.,In: **Physical Pharmacy:Physical Chemical Principles in the Pharm. Sciences**, 4 Edn., B.I Waverly, Pvt. Ltd., 54, Janpath, New Delhi, 257, 1994.
7. Bekers 0., Uijtendaal, E.V., Beijnen, J.H., Bult, A. and Underberg, W.J.M., **Drug Dev. Ind. Pharm**.,17, 1503, 1991.
8. Loftsson, T. and Brewster, M.E., **J. Pharm. Sci.,** 85, 1017, 1996.
9. Rajewski, R.A. and Stella, V.J., **J. Pharm. Sci.,** 85, 1142, 1996.
10. Nash, R.A.,In: **Hand book of Pharmaceutical Excipients,** Wade, A., Weller, P.J., Eds., Am. Pharm.Assoc. & Phar. Press: London, 145, 1994.
11. Szejtli, J., **Cyclodextrin Technology,** Kluwer. Academic Publishers, Dordrecht, The Netherlands,1988.
12. Szejtli, J., **Drug Investigation,** 2(suppl.), 11, 1990.
13. Szejtli, J., **Cyclodextrins and their inclusion complexes,**Akademiai, Kiado, Budapest, Hungary, p.13, 1982.
14. Chiou W. L and Riegelman S. Pharmaceutical applications of solid dispersion systems. **J. Pharm**. *Sci.* 1971; 60:1281-1302.
15. Hancock B.C. and Zogra G., Characteristics and significance of the amorphous state in pharmaceutical system (review). **J.Pharm**. 1997; 86:1-12.
16. Khidr sh; Effect of block copolymers on the dissolution of some water-insoluble drugs. Part 1,nifedipine-pluronic F-127 solid dispersions system; **Bull-pharm-sciassiut- univ**.1994; 17(1):81-86.
17. Kumar DS et al; Solubility improvement using solid dispersion; strategy, mechanism and characteristics: responsiveness and prospect way outs; **International Research Journal of Pharmacy,** 2011, Vol. 2, p.55-66
18. Sharma D, Soni M, Kumar S and Gupta GD; Solubility Enhancement –Eminent Role in Poorly Soluble Drugs; **Research Journal of Pharmacy and Technology***;* 2009, Vol. 2, p. 220-224.

19. Vasconcelos TF, Sarmento B and Costa P; Solid dispersion as strategy to improve oral bioavailability of poor water soluble drug; **Drug Discovery Today,** 2007, Vol. 12, p. 1068-1075.

20. Kamalakkannan V, Puratchikody A, Masilamani K and Senthilnathan B; Solubility enhancement of poorly soluble drugs by solid dispersion technique – A review; **Journal of Pharmacy Research**,2010, Vol. 3, p. 2314-2321.

21. www.drugbank.ca/drugs/DB 00177.

22. http://en.wikipedia.org/wiki/Valsartan.

23. Angiotensin II Receptor Blockers: Current Perspective V Agrawal*, G Manohar**, RR Kasliwal JAPI • VOL. 51 • July 2003 706-716.

24. Foyes principles of medicinal chemistry thomas l.lamke, david a. Williams, 6th Edition Lippincott Williams & Wilkins, 753-758.

25. www.drugbank.ca/drugs/DB 00107.

26. http://en.wikipedia.org/wiki/Irbesartan.

27. Angiotensin II Receptor Blockers: Current Perspective V. Agrawal, G. Manohar, R.R. Kasliwal.**J.A.P.I**., VOL. 51 July 2003 706-716.

28. Foyes principles of medicinal chemistry thomas l.lamke ,david a. Williams,6th Edition Lippincott Williams & Wilkins,753-758.

29. www.drugs.com/ppa/telmisartan.

30. http://dailymed.nlm.nih.gov/wili/Telmisartan.